Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
EVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.84 - $5.64
Previous CloseN/A
Volume32.72K
Average Volume (3M)79.23K
Market Cap
$1.43B
Enterprise Value$1.48B
Total Cash (Recent Filing)$378.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 13, 2025EPS Estimate
-0.07Last Dividend Ex-Date
Jan 11, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding355,533,080
10 Day Avg. Volume108,090
30 Day Avg. Volume79,230
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit13.79
Enterprise Value/Ebitda-9.91
Forecast
1Y Price Target
$6.00Price Target Upside49.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company noted that it has made significant progress on cost out initiatives and expects additional positive impact over the coming quarters.
Growth StrategyManagement refined their new near-term growth strategy favoring higher-margin mix shift, and better-than-expected impacts from the now complete Priority Reset.
Revenue GrowthGuidance of 5-10% revenue growth in 2025 is encouraging.
Bears Say
Funding UncertaintiesPharma funding uncertainties are impacting demand, leading to light Shared R&D revenues.
Market EnvironmentShared R&D was affected by the overall soft biotech market environment.
R&D RevenuesWeakness in the Shared R&D segment alongside ramping expenses tied to bringing the Toulouse facility online will likely remain an overhang on the near-term outlook.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.84 and its highest was $5.64 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.43B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Aug 13, 2025 which is in 8 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.07.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,533,080 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
Evotec AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (49.25% Upside)
$6.00 (49.25% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.17%
12-Months-Change
Fundamentals
Return on Equity
-20.41%
Trailing 12-Months
Asset Growth
-11.93%
Trailing 12-Months
Company Description
Evotec AG
Evotec AG is a global biotechnology company headquartered in Hamburg, Germany. It operates in the healthcare and life sciences sectors, focusing on drug discovery and development. The company provides integrated research and development services to pharmaceutical and biotechnology companies, academic institutions, and foundations. Evotec's core services include early-stage discovery, pre-clinical, and clinical development of small molecules, antibodies, and other biologics across various therapeutic areas, including oncology, neurology, and infectious diseases.
EVO Company Deck
EVO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in the Just - Evotec Biologics segment and progress in strategic collaborations offset by declines in Shared R&D revenue and overall group revenue. Cost reduction initiatives are on track, but the increased net debt and leverage pose challenges.Read More>EVO Stock 12 Month Forecast
Average Price Target
$6.00
▲(49.25%Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Harrow Health
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.55% Other Institutional Investors
98.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---